Ascletis Acquires China Rights to Alphamab\'s PDL1 for Hepatitis B

Ascletis Acquires China Rights to Alphamab's PD-L1 for Hepatitis B

Ascletis Pharma of Hangzhou acquired China rights to a Suzhou Alphamab anti-PD-L1 candidate for hepatitis B and other viral disease indications. Ascletis will make an upfront payment, and Alphamab will be eligible to receive payments for development and commercial milestones plus royalties ranging from the mid-teens to around twenty percent. Alphamab will manufacture the candidate. Ascletis will be eligible to share in future upfront, milestone and royalty if ASC22 (KN035) is approved to treat viral diseases outside of Greater China. More details....

Stock Symbol: (HK; 1672) 

Share this with colleagues:

Original Article: Ascletis Acquires China Rights to Alphamab's PD-L1 for Hepatitis B

More From BioPortfolio on "Ascletis Acquires China Rights to Alphamab's PD-L1 for Hepatitis B"